Close
Smartlab Europe
Inizio Ignite

Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Bristol Myers Evinova Partnership Targets AI-Led Trials

Bristol Myers Squibb has entered a global agreement with...

Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies

Eli Lilly has agreed to acquire in vivo CAR-T...
- Advertisement -

Gilead Sciences Inc announced that its corporate presentation will be webcast from the Bank of America Merrill Lynch Healthcare Conference in Las Vegas.

Paul R. Carter, Gilead’s Executive Vice President, Commercial Operations, will provide an overview of the company at the conference on Tuesday, May 10 at 9:20 a.m. Pacific Time.

The live webcast can be accessed at the company’s Investors page at www.gilead.com/investors. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be required to listen to the webcast. The replay will be available for 14 days following the presentation.

About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Source: Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Investor Relations
Gilead Sciences, Inc.

Latest stories

Related stories

Novartis Breaks Ground on San Diego Biomedical R&D Site

Novartis has started work on a $1.1 billion biomedical...

Bristol Myers Evinova Partnership Targets AI-Led Trials

Bristol Myers Squibb has entered a global agreement with...

Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies

Eli Lilly has agreed to acquire in vivo CAR-T...

Study Finds Fenebrutinib Cuts Disability Progression In PPMS

Roche announced late-breaking Phase III data showing that fenebrutinib...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »